Why BioNTech Is Blasting Higher Today

A coronavirus stock if ever there was one, BioNTech (NASDAQ: BNTX) was rising by around 5% in late trading Friday on some excellent regulatory news. It seems that its star product is headed for even greater prominence.

That product is BNT162b2, the coronavirus vaccine BioNTech developed with its big partner, pharmaceutical industry giant Pfizer (NYSE: PFE). BioNTech happily announced Friday morning that the Food and Drug Administration (FDA) has granted the two companies its Priority Review designation for their Biologics License Application for BNT162b2.

Image source: Getty Images.

Continue reading

Source Fool.com